ABIONYX Pharma: Availability of the Universal Registration Document
May 02 2023 - 11:00AM
Business Wire
Regulatory News:
ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible),
a new generation biotech company dedicated to the discovery and
development of innovative therapies for patients, announces that it
has filed with the “Autorité des Marchés Financiers” (AMF) its
Universal Registration Document for the year ended December 31,
2022, dated April 28, 2023.
ABIONYX Pharma's Universal Registration Document for the
financial year ending December 31, 2022, includes in
particular:
- The annual financial report for 2022, consisting of the
consolidated financial statements, the annual financial statements
and the related statutory auditors' reports;
- The management report;
- The corporate governance report;
- A description of the share buyback program.
This document is available on the company's website
(www.abionyx.com) and on the AMF website (www.amf-France.org). It
is also available at the company's registered office, 33-43 avenue
Georges Pompidou - Building D, Balma, 31130.
The Universal Registration Document has also been published in
European Single Electronic Format (ESEF), with the five tables of
the consolidated financial statements (the primary financial
statements) and the appendix marked up using the XBRL markup
language.
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company that aims to
contribute to health through innovative therapies in indications
where there is no effective or existing treatment, even the rarest
ones. Thanks to its partners in research, medicine,
biopharmaceuticals and shareholding, the company innovates on a
daily basis to propose drugs for the treatment of renal and
ophthalmological diseases, or new HDL vectors used for targeted
drug delivery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230502005884/en/
NewCap Investor relations Louis-Victor Delouvrier Nicolas
Fossiez abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 94 98
Abionyx Pharma (EU:ABNX)
Historical Stock Chart
From Apr 2024 to May 2024
Abionyx Pharma (EU:ABNX)
Historical Stock Chart
From May 2023 to May 2024